Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingMass General Brigham PSMA Imaging Coverage | OpenP…
    Ask Trek AI about this page
    ModifiedMass General Brigham Health PlanPolicy 049

    Prostate-Specific Membrane Antigen Imaging for Patients with Prostate Cancer

    Customize your policy alerts

    Sign up for Mass General Brigham Health Plan Policy 049 alerts

    Get alerted when Policy 049 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization for PSMA-targeted PET imaging, with or without CT, in adult members with prostate cancer, including plan-specific requirements for Medicare Advantage, Mass General Brigham ACO, One Care/SCO, and Commercial and Qualified Health Plan members.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyProstate-Specific Membrane Antigen Imaging for Patients with Prostate Cancer
    Policy CodePolicy 049
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewNov 1, 2026
    Next Review DateNot scheduled
    Key ActionObtain prior authorization for PET and PET/CT procedure codes 78812, 78813, 78814, 78815, and 78816 for Medicare Advantage and Commercial or Qualified Health Plan members.
    SourceLink
    POLICY UPDATE CHANGES

    The policy criteria were updated in July 2025 based on the latest NCCN guidelines.

    Gozellix was added to the policy information and code list in February 2026.

    The prior authorization table and member-plan variations were updated in January 2026.

    The code list was updated during the November 1, 2026 ad hoc review.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Clinical coverage pathways
    3 monthsRecent PET/CT exclusion
    5PET/CT codes requiring prior authorization
    7Radiotracer codes without authorization requirement

    Medical Necessity Requirements

    Initial Workup of Prostate Cancer

    Covered for adult members with prostate cancer when <strong>one</strong> of the following initial workup criteria is met:

    ONE of the following

    • Unfavorable intermediate-risk disease.
    • High-risk disease.
    • Very high-risk disease.
    • Inconclusive bone findings on both CT/MRI and bone scan.
    • Conventional imaging studies (CT and bone scan) suggest minimal or low-volume metastatic disease that needs further evaluation.

    Restaging/Recurrence of Non-Metastatic Prostate Cancer

    Covered for restaging or recurrence of non-metastatic prostate cancer when <strong>all</strong> of the following are met:

    ALL of the following

    • Previously treated with prostatectomy or radiation therapy.
    • ONE of the following PSA criteria

      • PSA persistence, defined as detectable PSA (0.1 ng/mL or greater) at 3 months postoperatively.
      • Rising PSA on two or more occasions.
      • PSA rises to at least 0.1 ng/mL if PSA was previously undetectable.
    • The member is a candidate for salvage local therapy.

    Suspected Progression in Previously Treated Metastatic Prostate Cancer

    Covered for workup of suspected progression in previously treated metastatic prostate cancer when <strong>both</strong> of the following are met:

    ALL of the following

    • Previously treated with a novel hormone therapy: abiraterone, enzalutamide, darolutamide, or apalutamide.
    • Previously treated with docetaxel.

    A PET/CT has been performed within the past 3 months.

    Code-Specific Coverage Rules

    Medicare Advantage: Prior Authorization RequiredCPT
    78812PET imaging skull base to mid-thigh
    78813PET imaging whole body
    78814Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)
    78815Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh
    78816Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body
    Medicare Advantage: No authorization requiredHCPCSCovered
    A9593Gallium ga-68 psma-11, diagnostic, (ucsf), 1 millicurie
    A9594Gallium ga-68 psma-11, diagnostic, (ucsf), 1 millicurie
    A9595Piflufolastat f-18, diagnostic, 1 millicurie
    A9596Gallium Ga-68 gozetotide, diagnostic (Illuccix), 1 mCi
    A9608Flotufolastat f18, diagnostic, 1 millicurie
    A9616Gallium ga-68 gozetotide (Gozellix), diagnostic, 1 millicurie
    A9800Gallium Ga-68 gozetotide, diagnostic (Locametz), 1mCi
    Mass General Brigham ACO: Not coveredHCPCSNot Covered
    A9608Flotufolastat f18, diagnostic, 1 millicurie
    Commercial and Qualified Health Plans: Prior Authorization RequiredCPT
    78812PET imaging skull base to mid-thigh
    78813PET imaging whole body
    78814Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)
    78815Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh
    78816Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body
    Commercial and Qualified Health Plans: No authorization requiredHCPCSCovered
    A9593Gallium ga-68 psma-11, diagnostic, (ucsf), 1 millicurie
    A9594Gallium ga-68 psma-11, diagnostic, (ucsf), 1 millicurie
    A9595Piflufolastat f-18, diagnostic, 1 millicurie
    A9596Gallium Ga-68 gozetotide, diagnostic (Illuccix), 1 mCi
    A9608Flotufolastat f18, diagnostic, 1 millicurie
    A9613Piflufolastat f 18 (pylarify truvu), diagnostic, 1 millicurie
    A9616Gallium ga-68 gozetotide (Gozellix), diagnostic, 1 millicurie
    A9800Gallium Ga-68 gozetotide, diagnostic (Locametz), 1mCi
    Postoperative PSA persistence
    ThresholdPSA >= 0.1 ng/mL
    Timing3 months postoperatively
    DefinitionDetectable postoperative PSA at or above 0.1 ng/mL at 3 months
    Recent PET/CT exclusion
    ExclusionA PET/CT has been performed within the past 3 months
    Lookback period3 months

    Authorization and Denial Risks

    Prior Authorization

    Medicare Advantage PET Prior Authorization

    For Medicare Advantage members, obtain prior authorization for PET and PET/CT services billed with the following procedure codes. The listed radiotracer codes do not require authorization.

    • Prior authorization required: 78812, 78813, 78814, 78815, 78816.
    • No authorization required: A9593, A9594, A9595, A9596, A9608, A9616, A9800.
    Prior Authorization

    Commercial/QHP PET Prior Authorization

    For Commercial and Qualified Health Plan members, obtain prior authorization for PET and PET/CT services billed with the following procedure codes. The listed radiotracer codes do not require authorization.

    • Prior authorization required: 78812, 78813, 78814, 78815, 78816.
    • No authorization required: A9593, A9594, A9595, A9596, A9608, A9616, A9800.

    Clinical and Imaging Context

    PSMA-targeted radiotracers, including Pylarify, Posluma, and Ga-68 PSMA-11/gozetotide, are used with PET to identify PSMA-positive prostate cancer lesions. PSMA PET supports initial staging or workup, detection of recurrence after definitive treatment, and evaluation of suspected progression in previously treated metastatic disease. In selected patients, PSMA PET may provide greater sensitivity and specificity for pelvic nodal, bone, and soft-tissue disease than conventional imaging.

    Clinical Definitions

    PSA persistence
    TermPSA persistence
    PSA levelDetectable PSA of 0.1 ng/mL or greater
    Timing3 months postoperatively
    Biochemical recurrence / PSA recurrence
    TermBiochemical recurrence / PSA recurrence
    Rising PSAPSA rising on two or more occasions
    Previously undetectable PSAPSA rises to at least 0.1 ng/mL after previously being undetectable

    Covered Clinical Pathways

    Initial Workup of Prostate Cancer

    Covered for initial workup when any one of the following indications is present.

    Initial workup indication: Unfavorable intermediate-risk, high-risk, or very high-risk prostate cancer; inconclusive bone findings on both CT/MRI and bone scan; or conventional imaging studies, including CT and bone scan, suggesting minimal or low-volume metastatic disease requiring further evaluation.

    Restaging or Recurrence of Non-Metastatic Prostate Cancer

    Covered for restaging or recurrence when all of the following are present.

    Non-metastatic restaging/recurrence indication: Prior treatment with prostatectomy or radiation therapy, PSA persistence or recurrence evidenced by detectable PSA at 3 months postoperatively, PSA rising on two or more occasions, or PSA rising to at least 0.1 ng/mL after previously being undetectable, and candidacy for salvage local therapy.PSA persistence: >= 0.1 ng/mL at 3 months postoperatively when applicable

    Repeat Imaging Restriction

    PET/CT frequency limit
    ModalityPET/CT
    Frequency limitDo not perform when a PET/CT has been performed within the prior 3 months
    Lookback periodPrior 3 months

    Prior Authorization Requirements

    Prior Authorization

    Prior authorization for PET/PET-CT procedure codes

    Obtain prior authorization for Medicare Advantage and Commercial or Qualified Health Plan members before billing PET/PET-CT procedure codes 78812, 78813, 78814, 78815, or 78816.

    • 78812
    • 78813
    • 78814
    • 78815
    • 78816
    Prior Authorization

    Prior authorization for One Care and SCO PSMA imaging

    Obtain prior authorization for PSMA imaging for members enrolled in One Care or Senior Care Options.

    Non-Covered Services

    The following are not covered: PET/CT performed within the past 3 months, and HCPCS code A9608 for Mass General Brigham ACO members.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyProstate-Specific Membrane Antigen Imaging for Patients with Prostate Cancer
    Policy CodePolicy 049
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewNov 1, 2026
    Next Review DateNot scheduled
    Key ActionObtain prior authorization for PET and PET/CT procedure codes 78812, 78813, 78814, 78815, and 78816 for Medicare Advantage and Commercial or Qualified Health Plan members.
    SourceLink
    On This Page
    Medical Necessity RequirementsCode-Specific Coverage RulesAuthorization and Denial RisksClinical and Imaging ContextClinical DefinitionsCovered Clinical PathwaysRepeat Imaging RestrictionPrior Authorization RequirementsNon-Covered Services
    Applies toPET/CT
    Prior Authorization

    One Care/SCO Prior Authorization

    Prior authorization is required for PSMA-11 PET, with or without CT, for members enrolled in One Care or Senior Care Options (SCO). Confirm the member's plan requirements before scheduling or performing the service.

    • Prior authorization required: Yes.
    • Applies to One Care and SCO plan members.
    Denial Risk

    Criteria Not Met

    Coverage may be authorized for adult members with prostate cancer undergoing PSMA-11 PET, with or without CT, only when one of the defined clinical pathways is satisfied. Denial risk applies when the applicable pathway criteria are not met or required documentation is absent.

    • Initial workup: The member does not have unfavorable intermediate-risk, high-risk, or very high-risk disease; inconclusive bone findings on both CT/MRI and bone scan; or conventional imaging suggesting minimal or low-volume metastatic disease requiring further evaluation.
    • Restaging/recurrence: The member was not previously treated with prostatectomy or radiation therapy; does not have qualifying PSA persistence or PSA rise; or is not a candidate for salvage local therapy. Qualifying PSA findings include detectable PSA of at least 0.1 ng/mL at 3 months postoperatively, rising PSA on two or more occasions, or a rise to at least 0.1 ng/mL after previously undetectable PSA.
    • Suspected progression of previously treated metastatic disease: The member was not previously treated with both a novel hormone therapy (abiraterone, enzalutamide, darolutamide, or apalutamide) and docetaxel.
    Denial Risk

    ACO Exclusion

    A9608 is not covered for Mass General Brigham ACO members. Do not submit this code as a covered service for ACO membership.

    • Not covered: A9608.
    • Applies to Mass General Brigham ACO members.
    Denial Risk

    Recent PET/CT Exclusion

    PSMA-11 PET/CT is excluded when a PET/CT has been performed within the preceding 3 months.

    • Verify the member's imaging history before requesting or performing the service.
    • Exclusion window: prior 3 months.

    Workup of Suspected Progression in Previously Treated Metastatic Prostate Cancer

    Covered for workup of suspected progression when both prior-treatment conditions are present.

    Previously treated metastatic progression indication: Prior treatment with abiraterone, enzalutamide, darolutamide, or apalutamide and prior treatment with docetaxel.